Effective pharmacotherapy of bipolar depression with mixed features defined by DSM-5 remains unclear in clinical treatment guidelines. Quetiapine (QTP) and valproate have potential treatment utility but are often inadequate as monotherapy. Meanwhile, the efficacy of combination therapies of QTP plus valproate or lithium have yet to be verified. Hence, we conducted a randomized controlled pilot study to evaluate the efficacy of QTP monotherapy in patients with bipolar depression with mixed features defined by DSM-5 and compared the combination therapy of QTP plus valproate (QTP + V) versus QTP plus lithium (QTP + L) for those patients who responded insufficiently to QTP monotherapy. Data was analyzed according to the intent-to-treat population. Generalized linear mixed model was performed by using “nlme” package in R software. A total 56 patients were enrolled, among which, 35 patients responded to QTP alone, and 11 and 10 patients were randomly assigned to QTP + V and QTP + L group, respectively. Nearly 60% enrolled patients responded to QTP monotherapy at the first two weeks treatment. No statistically significant difference in efficacy between QTP + V and QTP + L was observed. In conclusion, QTP monotherapy appeared to be efficacious in patients with bipolar depression with mixed features, and for those who responded insufficiently to QTP, combining with either valproate or lithium appeared to have positive effects.
Aims: We aimed to investigate whether peripheral T‐cell subsets could be a biomarker to distinguish major depressive disorder (MDD) and bipolar disorder (BD). Methods: Medical records of hospitalized patients in the Department of Psychiatry, the First Affiliated Hospital, Zhejiang University School of Medicine, from January 2015 to September 2020 with a discharge diagnosis of MDD or BD were reviewed. Patients who underwent peripheral blood examination of T‐cell subtype proportions, including CD3+, CD4+, CD8+ T‐cell, and natural killer (NK) cells, were enrolled. The Chi‐square test, t ‐test, or one‐way analysis of variance were used to analyze group differences. Demographic profiles and T‐cell data were used to construct a random forest classifier‐based diagnostic model. Results: Totally, 98 cases of BD mania, 459 cases of BD depression (BD‐D), and 458 cases of MDD were included. There were significant differences in the proportions of CD3+, CD4+, CD8+ T‐cell, and NK cells among the three groups. Compared with MDD, the BD‐D group showed higher CD8+ but lower CD4+ T‐cell and a significantly lower ratio of CD4+ and CD8+ proportions. The random forest model achieved an area under the curve of 0.77 (95% confidence interval: 0.71–0.83) to distinguish BD‐D from MDD patients. Conclusion: These findings imply that BD and MDD patients may harbor different T‐cell inflammatory patterns, which could be a potential diagnostic biomarker for mood disorders.